Adult Dosing
Seasonal, perennial allergic rhinitis
Adults and adolescents >12 yrs
- Start with 2 sprays/nostril qd
- Max: 220 mcg/day
- 1 spray/nostril qd (110mcg/day) once symptoms are under control
- If no improvement occurs in 3 wks, discontinue use
Pediatric Dosing
- Safety and efficacy in pediatrics <2 yrs of age have not been established
Seasonal, perennial allergic rhinitis
Child 2-5 yrs
- 1 spray/nostril qd (110mcg/day)
- If no improvement occurs in 3 wks, discontinue use
- Max: 110 mcg/day
Child 6-12 yrs
- 1 spray/nostril qd (110mcg/day)
- 2 sprays/nostril qd (220mcg/day) if no adequate response to prior dose
- Reduce dose to 110 mcg qd as condition improves
- If no improvement occurs in 3 wks, discontinue use
[Outline]
See Supplemental Patient Information
- Epistaxis, nasal septal perforation, candida albicans infection, impaired wound healing have occurred; monitor patients for such adverse events
- Avoid use in patients with recent nasal septal ulcers, nasal surgery, or trauma
- Reevaluate if no improvement in 3 weeks
- Development of glaucoma or posterior subcapsular cataracts may occur. Closely monitor patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts
- In long term treatment, periodically perform nasal examinations due to the risk of nasal septal perforation and localized infections
- Hypercorticism and adrenal suppression with very high dosages or at the regular dosage in susceptible individuals may occur
- Discontinue therapy if hypercorticism and adrenal suppression occur with very high/regular dosages
- If exposed to measles or chickenpox, consider anti-infective prophylactic therapy
- Monitor growth in pediatric population as it may cause growth retardation
- If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with topical corticosteroids may exacerbate symptoms of adrenal insufficiency
- Patients may experience symptoms of corticosteroid withdrawal if systemic therapy is replaced with topical therapy; e.g., joint and/or muscular pain, lassitude, and depression
- Avoid contact with eyes
Cautions: Use cautiously in
- Respiratory tract tuberculosis
- Untreated local or systemic fungal or bacterial infections
- Diabetes
- Recent nasal trauma
- Nasal septal ulcers
- Systemic glucocorticoid therapy
- Ocular herpes simplex infection
- Measles or varicella exposure
- Nursing mothers
Supplemental Patient Information
- Avoid contact with eyes
- Advise patient to notify physician if symptoms do not improve within 3 wks, if symptoms worsen, or if nasal irritation occurs
- Use on a regular once-daily basis for optimal effect
- Instruct patients to not blow their nose for 15 minutes after using the spray
- Maximum benefit may not be reached for up to one week
Pregnancy Category:C
Breastfeeding: Amounts of inhaled triamcinolone absorbed into the bloodstream are too small and would not be expected to cause any adverse events on breastfed infants. This information is based on LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 2 December 2010).
US Trade Name(s)
- Nasacort AQ
- Nasacort allergy 24 Hour
US Availability
triamcinolone (generic)
- Metered nasal SPRAY: 55 mcg/spray
Nasacort AQ
- Metered nasal SPRAY: 55 mcg/spray
Nasacort allergy 24 Hour
- Metered nasal SPRAY: 55 mcg/spray
Canadian Trade Name(s)
Canadian Availability
Nasacort
- Metered aerosol for INH: 100 mcg/INH
Nasacort AQ
- Metered dose SPRAY: 55 mcg/spray
UK Trade Name(s)
- Nasacort Nasal Spray
- Nasacort Allergy Nasal Spray
UK Availability
Nasacort Nasal Spray
- Metered dose SPRAY: 55 mcg/spray
Nasacort Allergy Nasal Spray
- Metered dose SPRAY: 55 mcg/spray
Australian Trade Name(s)
Australian Availability
Telnase
- Metered dose SPRAY: 55 mcg/spray
[Outline]
2 yrs of age